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Prevalence of GvHD
100 days (n 5 37*) 1 yr (n 5 32*) Latest F/U (n 5 18*)
Donor type Related Unrelated Related Unrelated Related Unrelated
Grade 2-4
AGvHD
4/16 (25%)2/21 (10%)1/15 (7%) 1/17 (6%)
Extensive
CGvHD
2/15 (13%)2/17 (12%) 3/8 (38%) 0/10 (0%)a
*n 5 Number of patients alive at day 100, alive at 1 yr and alive at
latest F/U which is longer than 1 yr after HSCT.
aFor related vs. unrelated, Fisher’s exact p 5 0.069. All other com-
parisons not significant with p . 0.1.
Poster Session I 77Twelve patients received a matched unrelated donor transplant, and
13 received a matched related donor transplant. Conditioning in-
cluded 1 of these 3 regimens: Busulfan, Fludarabine, and Alemtuza-
mab or rATG (N5 19); Busulfan, Cyclophospamide and ATG (N
5 2); or Cyclophosphamide and rATG (N5 4). Percent donor en-
graftment in the CD31 subset and whole blood chimerism
(WhBCh) was determined using short tandem repeats. Testing
started around day 130, and it was repeated every 2–4 weeks until
stable CD31 and WhBCh was achieved. Median follow up for liv-
ing patients was 16 mos (4–62 mos).
All patients initially engrafted. We observed 6 chimerism patterns
as shown in Table 1. Seventeen patients (68%) remained mixed chi-
mera for the duration of follow-up. A majority of patients (71%)
with mixed chimerism had either very low (\20%) or fluctuating
CD31 cell chimerism. One of four patients with declining
WhBCh, discordant with slowly increasing CD31 chimerism, de-
veloped late graft failure at 8 months post transplant, and underwent
a 2nd transplant. Both patients with a precipitous decline in CD31
and WhBCh rejected their grafts by 2 months post transplant. This
was the only pattern predictive of graft rejection. Low percentage or
fluctuations in donor CD31 chimerism, in light of stable WhBCh,
were not predictive of graft rejection or clinical outcome.207
OCCURRENCE OF GRAFT VERSUS HOST DISEASE AFTER HEMATOPOI-
ETIC STEM CELL TRANSPLANT UTILIZING REDUCED INTENSITY CONDI-
TIONING IN PEDIATRIC PATIENTS
Danner-Koptik, K.1, Fu, J.3, Dilley, K.J.1,2. 1 Children’s Memorial Hos-
pital, Chicago, IL; 2 Northwestern University, Chicago, IL; 3 The Ohio
State University, Columbus, OH.
Background: Reduced intensity conditioning (RIC) regimens
are used as an alternative to traditional myeloablative conditioning
(TMC) for allogeneic hematopoietic stem cell transplant (HSCT)
in children. The main rationale is to allow tumor kill while decreas-
ing the degree of toxicity due to conditioning regimen. Objective:
To examine the occurrence of acute (A) and chronic (C) GvHD in
pediatric patients who received a RIC HSCT. Methods: Medical
record review of all patients who received a RIC HSCT from
2000 to the present at a single institution. Patients who ever re-
ceived a TMC HSCT or who had .1 RIC HSCT were excluded.
AGvHD data was collected at 100 days and 1 year; CGvHD was ex-
amined at 1 yr and latest follow-up (F/U). Results: Since 2000, 86
pediatric patients have undergone RIC HSCT for both malignant
(55%) and non-malignant (45%) diseases. 57% were male. All pa-
tients received a common backbone for conditioning including flu-
darabine and busulfan, plus or minus ATG or extracorporeal
photopheresis. At analysis, 27 patients were excluded for having re-
ceived a TMC HSCT and 15 more were excluded for .1 RIC
HSCT, with 44 patients who received a single RIC HCST included
in all further analyses. 17/44 (39%) transplants had related donor
peripheral blood stem cells as a donor source (related), which are
subsequently compared to all other sources (unrelated). Related do-
nor transplants were done at recipient mean age 7.8 yr vs unrelated
9.2 yr (p5 0.45). 68% of patients analyzed are currently alive, 18/44
(41%) alive at.1 yr from HSCT. GvHD was seen at the examined
timepoints in 23% (10/44) of patients overall, with 14% (6/44) hav-
ing AGvHD only, 11% (5/44) CGvHD only and 9% (4/44) experi-
encing both. No differences were found in occurrence of grade 2–4
AGvHD or extensive CGvHD at examined timepoints when com-
paring donors, except a trend toward more AGvHD at 100 days and
more CGvHD at latest F/U for related donors (see table). Conclu-
sion: It has been hypothesized that a RIC regimen will lead to less
recipient tissue damage with less inflammatory cytokine release and
may result in fewer toxicities and less GvHD. In pediatric RIC
HSCT we demonstrate a low prevalence of grade 2–4 acute and ex-
tensive chronic GvHD during a short F/U period, with no statisti-
cally significant differences between related and unrelated donor
stem cell sources. Future study with case-matched controls receiv-
ing TMC HSCT will help determine whether toxicity and GvHD
are reduced in RIC HSCT.208
THE USE, SAFETY, AND EFFICACY OF DACLIZUMAB FOR STEROID RE-
FRACTORY GRAFT-VERSUS-HOST-DISEASE (GVHD) AFTER UNRELATED
CORD BLOOD TRANSPLANTATION (UCBT)
Mohamed, A.1, Niedzwiecki, D.2, Baker, J.H.1, Vinesett, R.1,
Martin, P.L.1, Driscoll, T.A.1, Prasad, V.K.1, Parikh, S.1,
Kurtzberg, J.1, Szabolcs, P.1. 1 Duke University, Durham, NC; 2 Duke
University, Durham, NC.
UCBT is a life-saving form of hematopoietic cell transplantation
(HCT), however GVHD can hamper success. Steroid refractory
GVHD increases the incidence and severity of infections, leads to in-
creased mortality by 6 months. Daclizumab, a humanized anti-CD25
antibody has been widely utilized for treating GVHD after favorable
reports (Blood 1994;84:1320, Blood 2000;95:83). It’s efficacy and
safety, however, has been questioned by a recent multicenter, double
blinded, randomized trial (Blood;2004:104:1559) showing inferior
100-day and 1 year survival. The efficacy and safety of daclizumab af-
ter UCBT, however is not known. We report here the results of a ret-
rospective analysis on a cohort of three hundred twenty nine (329)
children who received a single UCB graft as first transplant between
1999 and 2005. All received myeloablative conditioning regimens,
ATG pre-UCBT and GvHD prophylaxis consisting of Cyclosporine
1Methylprednisolone (MPDN) or MMF (last 12 pts).
Results: Daclizumab was used to treat steroid refractory GVHD
in 89 patients (27%). 58 patients started therapy at a median of 36
days (mean 366 19) post-UCBT for acute GVHD, while 31 started
significantly later at a median of 207 days (mean 3866 452). Those
who received Daclizumab for acute GVHD (n5 58) were analyzed
and compared to the 239 patients who never received the drug (most
with grade 0-I GVHD). In univariate analysis, patients receiving
Daclizumab were significantly younger (mean 5.1 vs 6.9 years, p
5 0.03), less likely to have malignancy (p 5 0.001) and received
TBI (p 5 0.004). There were no differences in gender, ethnicity,
CMV serology, HLA-mismatch, TNC, CD31, and CD341 cell
dose/kg. OS at 6 months was comparable between these groups,
(57% versus 65% Chi-Square p 5 0.23). After 42 days of therapy,
response was scored based on IBMTR consensus criteria. 10 pa-
tients did not complete therapy due to death in 9; [relapse (3),
pre-existing infections (4), multiorgan failure (2)] Of those evalu-
able at D42, overall GVHD severity was downgraded in 35 of 46
(76%). MPDN was reduced from a mean of 2.0 mg/kg/day to
0.90 mg/kg/day by D42. Skin GVHD was downgraded to stage
0–1 in 45 of 46 patients. 11 patients with gut GVHD stages 2–4 im-
proved to stage 0–1 while 8 either failed to respond or worsened to
$stage 2. None of the three patients with liver GVHD (stages 3–4)
responded. Conclusion: Daclizumab therapy in UCBT recipients
appears safe with excellent response in skin but modest response
for visceral GVHD.
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UMBILICAL CORD BLOOD STEM CELL TRANSPLANTS FOR NONMALIG-
NANT HEMATOPOIETIC DISORDERS
Willert, J.1, Rosenthal, J.2, Brown, H.L.3, David, H.T.4. 1 Rady Chilren’s
Hospital of San Diego, San Diego, CA; 2 City of Hope, Duarte, CA; 3 CBR
Systems, Inc., San Bruno, CA; 4 University of Arizona, Tucson, AZ.
78 Poster Session IObjective:Cord blood stem cells are routinely used in transplant
for hematological malignancies. Many nonmalignant disorders,
particularly genetic disorders, require allogeneic transplantation,
but autologous transplantation is also possible. This report docu-
ments 17 cord blood units (CBU) released by one bank for treat-
ment of nonmalignant hematopoietic disorders. Methods: Cord
blood was collected from the umbilical cord of consenting mothers
who elected to store CBU, however, directed donation was offered
to families with an individual diagnosed with a disease treatable with
stem cells. The whole blood product was processed at the Cord
Blood Registry laboratory in Tucson, AZ to separate mononuclear
cells (MNC) from red blood cells and non-engrafting cells. The
processed CBU were cryopreserved until requested for use. Prior
to release, viability and HLA were assessed.Results:Of 56 CBU re-
leased for transplant, 17 (30.4%) were for nonmalignant disorders: 3
thalassemia, 2 Fanconi anemia, 1 Hurler syndrome, 2 sickle cell ane-
mia, 6 aplastic anemia, 1 x-linked hyper IGM syndrome, 1 Diamond
Blackfan anemia, and 1 Wolman disease. 13 (76.5%) of 17 were
from a sibling, but 4 aplastic anemia transplants were autologous.
The 17 samples were stored a mean of 28.38 months (range: 2–
114), mean patient age was 5.4 years, and mean period of engraft-
ment was 18.94 days (range: 2–36), with a mean of 0.77%
CD341 cells. All units were viable for transplant. The patient
with Wolman disease died 17 days post-transplant due to unrelated
complications, engraftment was not evaluable. Conclusion: Cord
blood stem cells are increasingly common for patients with nonma-
lignant blood and marrow disorders, and the availability of sibling
cord blood decreases risk of transplant-related morbidity and mor-
tality. Nonmalignant disorders represent a third of all transplants
facilitated by this family bank, suggesting that they are a significant
indication for cord blood transplantation. Directed donation or pri-
vate banking should be considered for siblings of patients with
a nonmalignant disorder treatable with stem cells.
Recipient Time EngraftmentDiagnosis RDonor
elationshipAge
(yrs) (Stored
months)
time PMN .
500 (days) StatusBeta Thalassemia Sibling 3.3 5 17 CuredFanconi Anemia Sibling 5.0 12 24 CuredHurler Syndrome Sibling 2.6 2 12 Deceased -
organ failure;
cardiomyopathySickle Cell Anemia Sibling 9.8 29 23 CuredAplastic Anemia Auto 2.7 32 36 Deceased -
infection;
aspergillusSickle Cell Anemia Sibling 2.4 2 35 CuredBeta Thalassemia Sibling 7.1 5 13 CuredX-linked Hyper
IGM SyndromeSibling 3.1 7 14 UnknownFanconi Anemia Sibling 11.5 27 13 Deceased -
hemorrhage
post-liver biopsyAplastic Anemia Auto 3.0 36 2 RemissionAplastic Anemia Sibling 2.9 6 27 RemissionBeta Thalassemia Sibling 0.3 44 16 CuredAplastic Anemia Auto 4.9 58 29 RelapsedAplastic Anemia Auto 9.6 114 21 RemissionAplastic Anemia Sibling 5.3 24 7 RemissionDiamond Blackfan
AnemiaSibling 10.1 24 14 CuredWolman Disease Sibling 0.2 27 Unevaluable Deceased -
respiratory
failure210
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FOR HEMATOLOGIC MALIGNANCIES AFTER REDUCED INTENSITY CON-
DITIONING (RIC) IN CHILDREN AND YOUNG ADULTS
Duerst, R.E., Jacobsohn, D.A., Tse, W., Schneiderman, J., Kletzel, M.
Children’s Memorial Hospital, Feinberg School of Medicine, Northwest-
ern University, Chicago, IL.RIC regimens and allogeneic HSCT are used to treat adults with
malignancies, relying on cellular graft-vs-malignancy effects. Age or
co-morbid conditions do not preclude treatment. RIC regimens
could potentially reduce long-term morbidity, enhancing the qual-
ity of life in pediatric survivors of HSCT.
We report the experience of 44 RIC HSCT for children/young
adult patients (pts) with hematologic malignancies, 33 at high-risk
for complications of full-intensity conditioning due to disease state,
prior HSCT (5 allo, 7 auto) and/or co-morbidities. The RIC regi-
men was comprised of fludarabine, 150 mg/m2 over 5 days, followed
by IV busulfan, 0.8–1 mg/kg for 8 doses (n 5 14) or targeted AUC
4000 microMol*min for 2 doses (n5 30) and ATG. 10 pts received
extracorporeal photopheresis (ECP), and not ATG.
Diagnoses included: ALL (18,$CR3 in 9), AML (9, refractory in
3), CML (6), Non-Hodgkin’s Lymphoma (5), Hodgkin’s Lym-
phoma (2) or treatment-related myelodysplastic syndrome (4).
There were 26 males, 18 females, ages 2–21 yrs, median 11. Stem
cell sources included 22 unrelated donors (URD), 20 matched
sibs and 2 mis-matched relatives. 42 of 44 stem cell donations
were mobilized peripheral blood. Graft-versus-host disease
(GVHD) prophylaxis was cyclosporin A (CsA) alone in 11 pts,
CsA and mycophenolate (MMF) in 24 pts or CsA with MMF and
post-HSCT ECP in 9 patients.
The median time to reach an ANC.500/mcl was 19 days (range
9–62). An unsupported Plt Ct. 20,000/mcl was achieved in 40 pts
at a median of 17 days (7–228), 14 pts required no platelet support. 2
pts with URD failed to engraft and 2 had graft loss. 8 pts developed
Gr III-IV acute GVHD, 11 of the 34 pts surviving more than 100
days developed chronic GVHD (5 limited, 6 extensive). Sustained
full (.95%) donor chimerism was achieved in 24 pts.
13 pts survive without disease relapse or progression. 22 pts re-
lapsed or had molecular evidence of persistent disease. Of these, 3
pts are alive in subsequent remission following immune modula-
tion, 5 are in remission after further therapy (4 HSCT) and 5 con-
tinue therapy. 9 pts died after disease recurrence. Another 9 pts have
died, 7 from opportunistic infections, 2 from hyperacute GVHD.
Thus, the projected 3-year survival in this very high-risk group of
pts is 44%.
Our results suggest a graft vs malignancy effect can be harnessed
and RIC allogeneic HSCT should be considered for pediatric pts,
especially those at high-risk for complications after conventional
HSCT.211
HAPLOIDENTICAL STEM CELL TRANSPLANTATION USING T- AND B-
LYMPHOCYTE DEPLETED GRAFTS FOLLOWING REDUCED INTENSITY
CONDITIONING FOR WISKOTT-ALDRICH SYNDROME
Kasow, K.A., Madden, R., Barfield, R., Leung, W., Hale, G.A. St. Jude
Children’s Research Hospital, Memphis, TN.
Wiskott - Aldrich syndrome (WAS) is a rare X-linked syndrome
characterized by micro- thrombocytopenia, eczema, and immuno-
deficiency, curable only through allogeneic hematopoietic stem
cell transplantation (HSCT). A mismatched family member is an
option when no matched related or unrelated donor is available.
Our team recently treated two young males, ages 1 year and 4 years,
who were enrolled on a prospective clinical trial using haploidenti-
cal HSCT for WAS. One donor was a 3/6 HLA-matched mother
and the other a 4/6-HLA matched father. A reduced intensity con-
ditioning (RIC) regimen consisting of fludarabine, thiotepa, mel-
phalan and OKT3 was administered. To reduce the risk of severe
graft-versus-host disease (GVHD) and EBV-lymphoma (PTLPD),
patients received a G-CSF mobilized peripheral blood stem cell
product depleted of T- and B-lymphocytes using the CliniMACS.
To facilitate engraftment, 1–2.5  105 CD31 cells/kg were added
to the graft. Cyclosporine was initiated on day -2 and continued un-
til day1100, then tapered in the absence of GVHD. The length of
hospitalization was 26 and 44 days. They received grafts containing
between 7.9–25.95  106 CD341 cells/kg and received 1.6–3.3 
104 CD191 cells/kg. Both demonstrated myeloid engraftment on
days 10 and 11 and achieved platelet engraftment of 50,000/mm3
by days 13 and 15. Only one patient, the one who received the lower
T-cell dose, experienced GHVD; he had grade 1 acute GHVD,
